Depomed rises on favorable 'Markman' pretrial hearing in patent dispute
This article was originally published in Scrip
Executive Summary
Shares of Depomed rose as high s 9.6% on 29 January after the company said it garnered a favorable "Markman" claim construction ruling by from a district court judge in a patent infringement case against filers of three abbreviated new drug applications (ANDAs) seeking to market generic versions of Gralise (gabapentin) before nine patents on the drug expire.